These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1069 related articles for article (PubMed ID: 6747294)

  • 21. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
    J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of immune complex-mediated complement activation by autoantibodies (F-42) isolated from sera of patients with systemic lupus erythematosus.
    Daha MR; Hazevoet HM; Vanes LA
    Clin Exp Immunol; 1983 Sep; 53(3):541-6. PubMed ID: 6604604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes.
    Garred P; Michaelsen TE; Aase A; Mollnes TE
    J Immunol; 1990 Jan; 144(1):198-203. PubMed ID: 2295791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-C1q column: ligand specific purification of immune complexes from human serum or plasma. Analysis of the interaction between C1q and immune complexes.
    Kilgallon W; Amlot PL; Williams BD
    Clin Exp Immunol; 1982 Jun; 48(3):705-14. PubMed ID: 6811171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes.
    Miletic VD; Hester CG; Frank MM
    J Immunol; 1996 Jan; 156(2):749-57. PubMed ID: 8543829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of activation of the classical pathway of complement by monoclonal IgE (DES). Restricted regulation of C4b by C4b-binding protein.
    Saint-Remy JM
    Eur J Immunol; 1984 Mar; 14(3):254-9. PubMed ID: 6608450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The failure to show a necessary role for C3 in the in vitro antibody response.
    Waldmann H; Lachmann PJ
    Eur J Immunol; 1975 Mar; 5(3):185-93. PubMed ID: 1086224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum.
    Schreiber AD; Frank MM
    J Clin Invest; 1972 Mar; 51(3):583-9. PubMed ID: 4622104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Control of the immune complex-complement interaction by protein H of the alternative complement pathway and the natural inhibitor heparin.
    Spycher MO; Nydegger UE
    Eur J Immunol; 1984 Mar; 14(3):276-9. PubMed ID: 6231187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Binding of soluble immune complexes to Raji lymphocytes. Role of receptors for complement components, C1q and C3-C3b.
    Gupta RC; McDuffie FC; Tappeiner G; Jordon RE
    Immunology; 1978 Apr; 34(4):751-61. PubMed ID: 102587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.
    Schifferli JA; Steiger G; Hauptmann G; Spaeth PJ; Sjöholm AG
    J Clin Invest; 1985 Dec; 76(6):2127-33. PubMed ID: 2934406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The modulation of immune complex aggregation by classical pathway-mediated reactions.
    Gronski P; Bodenbender L; Kanzy EJ; Loos M; Seiler FR
    Immunobiology; 1985 May; 169(4):346-61. PubMed ID: 3874147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Killing of the S and Re forms of Salmonella minnesota via the classical pathway of complement activation in guinea-pig and human sera.
    Clas F; Loos M
    Immunology; 1980 Aug; 40(4):547-56. PubMed ID: 6776034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of specific antibody on antibody-independent interactions between E. coli J5 and human complement.
    Betz SJ; Page N; Estrade C; Isliker H
    J Immunol; 1982 Feb; 128(2):707-11. PubMed ID: 7033382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activation of complement by isolated human heart subcellular membranes.
    Giclas PC; Pinckard RN; Olson MS
    J Immunol; 1979 Jan; 122(1):146-51. PubMed ID: 762412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model.
    Wagner E; Platt JL; Howell DN; Marsh HC; Frank MM
    J Immunol; 1999 Sep; 163(6):3549-58. PubMed ID: 10477630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sheep serum complement sensitisation of sheep erythrocyte-rabbit antibody complexes for haemolysis by guinea-pig complement plus EDTA or Mg2+-EGTA.
    Jonas W; Stankiewicz M
    Arch Immunol Ther Exp (Warsz); 1986; 34(4):451-60. PubMed ID: 3099725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complement fixation in acute serum sickness: assembly of glomerular-bound C3-convertase.
    Bartolotti SR; Peters DK
    Clin Exp Immunol; 1979 Sep; 37(3):391-8. PubMed ID: 389495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.